Menu Search
Equities

Enhabit Inc

X34:FRA

Enhabit Inc

Actions
  • Price (EUR)7.85
  • Today's Change-1.00 / -11.30%
  • Shares traded250.00
  • 1 Year change-29.91%
  • Beta--
Data delayed at least 15 minutes, as of May 10 2024 11:41 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Enhabit, Inc. is a provider of home health and hospice services. The Company’s segments include Home Health and Hospice. The Home Health segment provides a range of Medicare-certified skilled home health services, including skilled nursing, physical, occupational and speech therapy, medical social work, and home health aide services. Its home health business benefits from a diversity of referral sources, with patients referred from acute care hospitals, inpatient rehabilitation facilities, surgery centers, assisted living facilities, and skilled nursing facilities, as well as community physicians. The Hospice segment provides hospice services for terminally ill patients and their families. Its Medicare-certified hospice operations provide hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and family member bereavement counseling. It operates over 110 hospice agencies and 255 home health agencies.

  • Revenue in USD (TTM)1.05bn
  • Net income in USD-80.50m
  • Incorporated2014
  • Employees10.80k
  • Location
    Enhabit Inc6688 N. Central Expressway, Suite 1300DALLAS 75206United StatesUSA
  • Phone+1 (469) 621-6419
  • Fax+1 (302) 655-5049
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.